Form 4: Marinus Pharmaceuticals SVP Martha Manning Reports Share and Option Disposals Following Merger Agreement

Martha Manning, SVP of Marinus Pharmaceuticals, reports the disposal of shares and stock options following the merger agreement with Immedica Pharma AB.

Summary

• Martha Manning, SVP, General Counsel & Corporate Secretary of Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports transactions occurring on February 7, 2025, and February 11, 2025, related to the acquisition of Marinus Pharmaceuticals by Immedica Pharma AB.
• Manning disposed of 12,186 shares of common stock on February 7, 2025, at a price of $0.55 per share.
• On February 11, 2025, Manning disposed of 48,077 shares underlying Restricted Stock Units (RSUs) and various stock options with exercise prices ranging from $1.4 to $12.6.
• These disposals are a result of the merger agreement where common stock was acquired at $0.55 per share, RSUs were terminated for a cash payment, and out-of-the-money stock options were terminated without payment.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports transactions related to a previously announced merger. The information is factual and doesn't inherently indicate positive or negative sentiment.

Future Outlook

The merger between Marinus Pharmaceuticals and Immedica Pharma AB is complete, leading to the disposal of shares and termination of stock options as outlined in the Merger Agreement.

Industry Context

This announcement reflects the completion of a merger transaction, a common occurrence in the pharmaceutical industry as companies seek to expand their portfolios, access new markets, or achieve synergies.

Stakeholder Impact

• Shareholders received $0.55 per share as part of the merger agreement.
• Employees with RSUs received a cash payment based on the offer price.
• Employees with out-of-the-money stock options did not receive any payment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Marinus Pharmaceuticals, MRNS, Immedica Pharma AB, Merger Agreement, Stock Options, Restricted Stock Units, Disposal, Martha Manning